The accumulation and infiltration of eosinophils in airways is one of the most important characteristics of asthma, and is mediated partly by secretion of IL-5 from Th2 lymphocytes. It is well known that interleukin-5 (IL-5) played an important role in the regulation of eosinophils. In this study, an anti-sense IL-5 gene transferred by recombinant adeno-associated virus (rAAV-ASIL-5) was prepared to transfect allergic rats. It was found that the expression of IL-5 protein in plasma and BALF were inhibited significantly. The rAAV-ASIL-5-mediated suppression of total cell counts in peripheral blood and BALF were also observed. Moreover, rAAV-ASIL-5 remarkably reduced the eosinophil counts in peripheral blood and BALF, as well as the expression of ECP protein in plasma and BALF. The inflammation in lungs of rAAV-ASIL-5 pretreated rats also became slighter when compared with allergic rats.
Introduction
Asthma is a complex chronic inflammation disease of airways which is characterized by reversible airway obstruction, bronchial hyper-reactivity and airway inflammation with eosinophils, mast cells and T lymphocytes infiltration (1) .
Eosinophil is thought to be major effecter cell in the inflammation process of asthma.
The accumulation and infiltration of airways eosinophils is one of the most important characteristics of asthma (2) . There is a strong association between airways eosinophils inflammation and the development of lung pathology in asthma. Activated eosinophils can release oxygen free radicals and toxic granule proteins, such as eosinophil cationic protein (ECP), major basic protein (MBP), eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN) and eosinophil peroxidase (EPO). ECP and MBP are highly cationic proteins with a number of biological activities of which the cytotoxic potency of the protein is more conspicuous. They may be assayed in most biological fluids as markers of eosinophil activity and turnover. EPO produces hypophalous acid capable of killing parasites by oxidizing halides (3) . In addition, activated eosinophils can also generate membrane derived lipid mediators, for instance platelet-activating factor (PAF) and leukotriene-C4 (LTC4), as well as reactive oxygen species that may add to their proinflammatory effects (4, 5) .
Eosinophils inflammation is considered as one of the most important contributors to the structural and functional changes in airways of asthma, including bronchial hyper-reactivity, damage to epithelial cells, hyperplasia of goblet cells, hypertrophy of the airway smooth muscle cells and fibrosis (6, 7) . The presence of eosinophils and their products in airways are recognized contributors to the disease severity and the development of airway hyper-reactivity in asthma (3, 8) .
Interleukin-5 (IL-5) is mainly produced by activated Th2 cells, a sort of CD4 + T lymphocytes. It has been long established that IL-5 is vital in promoting eosinophils proliferation, differentiation and survival (9) . Previous researches revealed that IL-5 is one of the most critical regulatory factors of eosinophils (10, 11) . IL-5 play an important role in activating eosinophils, preventing eosinophils apoptosis, inducing eosinophils precursor cells differentiation, and encouraging toxic granule proteins and inflammation mediators secreting from eosinophils (12, 13) . Furthermore, IL-5 has the functions of gathering eosinophils, reinforcing antigen-inducing eosinophils degranulation reaction, and enhancing antibody-dependent cytotoxic effect (14) .
Therefore, as a sort of representative cytokine produced from overplenty Th2 cells in asthma, IL-5 may act a vital role in the development of asthma. The suppression of IL-5 is theoretically beneficial to therapy for asthma.
Preceding researches revealed that anti-IL-5 therapy could suppress the airway inflammation and hyper-reactivity in asthmatic mice. Eosinophils and airways
hyper-reactivity to inhaled methacholine did not develop in OVA sensitized and challenged IL-5-deficient BALB/c mice (15) . An anti-sense oligonucleotide of IL-5 significantly inhibited eosinophils in vivo, coincided with specifically reduce of IL-5 protein level in both the murine OVA challenged and allergic peritonitis models (16) .
The treatment of anti-IL-5 antibody also had remarkable anti-inflammation effects on OVA sensitized and challenged BALB/c mice, including decreasing the numbers of both intraepithelial eosinophils and chronic inflammatory cells in the airway wall, inhibiting the development of subepithelial fibrosis et al (17) . Many clinic studies (24, 25) . The AAV is effective as a vector as it contains sufficient carrying capacity for the insertion of many sorts of exogenous genes. As a result, it is possible for exogenous gene to produce a sustained and marked effect through persistent expression (26, 27) . In this way, finding a long-term treatment method could become easier.
In our past research (28) 
Materials and Methods

Construction of plasmid pSNAV-ASIL-5 and pSNAV-EGFP
Vector plasmid pSNAV (29) weeks. The aerosol was generated with an ultrasonic nebulizer (Shanghai KODAK instrument Equipment Co. LTd. China) and was drawn into an exposure chamber containing awaked animals. The output of the nebulizer was 3ml/min and the medium particle size was about 3.2μm according to specifications by the manufacturer.
Animals in group N received a subcutaneous injection of 1 ml normal saline and were exposed to aerosolized normal saline.
Gene delivery
Animals in group T and group C were pretreated with rAAV-ASIL-5 and rAAV-EGFP 0.5ml (1×10 13 v.g./ml) respectively on the day before sensitizing (day 0) and the day before challenge (day 13) via tail vein injection. Virus vectors were replaced by normal saline in group N and group A.
Collecting samples
Twenty-four hours after the last exposure to OVA or normal saline, all rats were anaesthetized by the intraperitoneal injection of 60 mg/kg pentobarbital. Animals were sterilized with 75% ethanol, fixed on operation table, opened the thoracic cavity, and draw blood from heart for cell count, extracted plasma.
After haemospasia of animal, rat right bronchus was cannulated by a tracheal cannula and lavaged with 3ml normal saline for bronchoalveolar lavage fluid (BALF).
BALF was recovered by gentle manual aspiration with a syringe. At the same time, Total numbers of nucleated cells in BALF were determined with a cells counting plate.
A differential cell count was performed by cell smears stained with Wright-Giemsa in duplicate, and was based on standard morphologic criteria of at least 300 cells with immersion objective microscope (34, 35) .
Detecting the level of ECP protein in plasma and BALF
Plasma and BALF was obtained as above described and saved at -80℃ for ELISA detection. The level of ECP protein in plasma and BALF were detected by rat ELISA kit (Rapid-bio, USA) as described above.
HE staining of tissues
The removed tissues of left lung, heart, liver and left kidney were fixed in 4%
(wt/vol) paraformaldehyde for 24 hours, all these tissues were embedded in paraffin and cut in 5μm-thick sections. Histological changes were evaluated on sections stained with hematoxylin and eosin (HE). The pathological variations were observed under microscope.
Statistical analysis
All data were expressed as mean ± standard deviation and analyzed by one-way ANOVA and q test using SPSS 12.0. A P value less than 0.05 was considered statistically significant.
Results
Effect of rAAV-ASIL-5 on expression of IL-5 protein in plasma and BALF
As shown in Figure 1 , OVA sensitization and challenge markedly increased the level of IL-5 protein in plasma and BALF when compared with normal rats (P<0.05
for both，group A versus group N). Treatment with rAAV-ASIL-5 significantly reduced the level of IL-5 protein in plasma and BALF (P<0.05 for both, group T versus group A), though they were still higher than normal rats (P<0.05 for both, group T versus group N). In contrast, treatment with rAAV-EGFP had little effect on the level of IL-5 protein in plasma and BALF.
Effect of rAAV-ASIL-5 on total white cells count and eosinophils count in peripheral blood
As compared with normal rats, OVA sensitization and challenge remarkably increased the count of total white cells in peripheral blood of (P<0.05, group A versus group N) (Figure 2 ). Treatment with rAAV-ASIL-5 significantly reduced the count of total white cells in peripheral blood (P<0.05, group T versus group A), but it was higher than normal rats (P<0.05, group T versus group N). On the contrary, treatment with rAAV-EGFP had no effect on the total count of white cells in peripheral blood.
Eosinophils, which were seen few in the blood of normal rat, were strikingly increased in allergic rats (P<0.05, group A versus group N) (Figure 2 ). The count of eosinophils in peripheral blood was reduced markedly with treatment of rAAV-ASIL-5 (P<0.05, group T versus group A), though still higher than normal rats (P<0.05, group T versus group N). However, treatment with rAAV-EGFP had no effect on the count of eosinophils in peripheral blood.
Effect of rAAV-ASIL-5 on nucleated cells count and eosinophils count in BALF
As compared with normal rat, OVA sensitization and challenge significantly were still higher than normal rats (P<0.05 for both, group T versus group N). On the contrary, treatment with rAAV-EGFP had almost no effect on the level of ECP protein in plasma and BALF.
Effect of rAAV-ASIL-5 on lung inflammation
We lastly observed the effect of rAAV-ASIL-5 on lung inflammation via the lung histological sections under microscope ( Figure 5 ). There was no accumulation or infiltration of eosinophils and few other inflammation cells in lung histological sections of normal rats. No visible bronchoconstriction was found either. In lung pathological sections of rat models of allergic asthma, severe inflammation was observed such as infiltration of eosinophils and lymphocytes, prolification of goblet cells, bronchial smooth muscle thickening and bronchoconstriction. With treatment with rAAV-ASIL-5, it showed mild inflammation, slight accumulation of eosinophils and lymphocytes, moderate bronchoconstriction in pathological sections of lung. However, the treatment of rAAV-EGFP had no effect on lung inflammation. We saw no apparent pathological abnormality in histological sections of heart, liver and kidney in all groups (figure not shown).
Discussion
Previous studies have revealed that interfere of targeting IL-5 had significant results in suppression of eosinophils and airway hyper-reactivity in animal models of allergic asthma (15) (16) (17) . Moreover, the anti-IL-5 therapy has shown prevention of eosinophils in clinic (18) (19) (20) . All these researches suggested that blocking the function of IL-5 in vivo maybe an important strategy for developing a novel therapeutic approach to treat allergic asthma and other eosinophilic diseases.
The rAAV vector, which either integrates into the genome or remains in the nucleus as a stable episome, offers attractive advantages and may be one of the most promising gene vector for long-term therapy. In our past research, we succeeded to 
